Central Nervous System DiseaseNCT07167043
An Explainable Neuroradiologist Artificial Intelligence Assistance System for Brain CT and MRI
An observational study of Central Nervous System Disease and MRI, run by Yaou Liu at 1 site in China.
Trial summary
This clinic trial aims to validate the working performance of radiologists with or without artificial intelligence (AI) diagnostic tool at neurological diseases diagnosis on brain CT/MRI. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Central Nervous System Disease, MRI, CT
- What is being tested?
- AI-assisted diagnostic systems
- How many people
- 30,000 participants
- Where
- 1 siteChina
- Study dates
- 1 May 2025to 1 Dec 2030
- How long will I take part?
- 5 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: All patient exams are of men suspected of harboring brain tumors or the other neurological diseases, with or without neurological symptoms, and without a history of prior brain surgery. Patients underwent brain CT and MRI, and were primarily examined at Beijing Tiantan hospital, between 2012-2026.
Who may be able to join
- For MRI: patients suspected of harboring brain tumors or detected with brain occupancy at initiating or other institution, who subsequently underwent brain MRI.
- For CT: patients with or without neurological symptoms, suspected of harboring ischemic, hemorrhagic, space-occupiing, degenerative brain disease, or traumatic brain injury, who subsequently underwent brain CT.
Who cannot join
- Patients who opted-out or did not give permission to reuse clinical data.
- Patients with a history of prior brain surgery.
- Patients whose brain CT or MRI exhibit severe artifacts (e.g. heavy warping due to air, metal artifacts, heavy motion artifacts), thereby impeding the usage of the data.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Reasoning Artificial Intelligence Collaborate With Radiologists in Neurological Disease Interpretation and Diagnosis on CT and MRI
This clinic trial aims to validate the working performance of radiologists with or without artificial intelligence (AI) diagnostic tool at neurological diseases diagnosis on brain CT/MRI. Routine diagnosis workflow in real clinical scenario including imaging reading, feature interpretation, differential diagnosis, writing initial report and optimizing revised version. And the gold standards of diagnosis are the histopathology references for brain tumors and the discharge diagnosis integrating all the examination results for the other neurological diseases. The performance of AI-assisted tools on diagnosing should be examined in a clinical process with multiple aspects identical to human radiologists' work before being transformed and putted to use. This study hypothesizes that AI models, trained with over 100,000 patient scans, are non-inferior to radiologists in neurological disease diagnosis on brain CT and MRI. For the secondary end-points, we investigate the performance of AI-radiologist collaboration of reasoning-enhanced AI-assisted systems. We hypothesize that, by visualizing the process of imaging interpretation and diagnosis, reasoning-enhanced AI can not only improve working performance of radiologists but also boost their trust in AI tools.
Read the detailed description
Neurological diseases affect over 50% of the world population, which contribute to an increasingly needs of imaging examination for screening and diagnosis. The shortage of neuroradiologists led to the excessive workload, linked with increasing of error rates and decreasing of report quality. Inexperienced radiologists struggle to make accurate diagnoses for some neurological diseases, especially brain tumors, which may lead to additional delays and a potentially meaningless examination for patients.
Artificial intelligence (AI) has shown potential to be "a tireless resident", which can rival human performance in medical imaging interpretation and assist radiologists in multiple links of clinical diagnostic work. However, clinicians recognize that "Black-box" models lacking clinical utility and interpretability face significant barriers to real-world deployment. While the reasoning-enhanced AI model, trained by a hundred thousand data, can not only achieve accurate and efficient diagnosis but also but also address the lack of explainability, transparency, and trust.
Owing to the heterogeneity of multi-modal real clinical data and complexity of neurological diseases, whether the developed AI-assisted system can truly serve as an "AI resident" facing challenges and doubts. Clinical trial is the best approach to verify the performance of diagnosis and human-machine collaboration of AI model with a wide range of users and prospective data before being approved for clinical use. Key aspects of the study design have been established in conjunction with a multi-disciplinary scientific advisory board, consisting with experts in AI, radiology, neurology, and pathology, to ensure meaningful validation of reasoning-enhanced AI model towards clinical translation.
This clinic trial contains two sub-studies:
- Clinical silence trial study for AI tools only: There are three approaches may be used in this stage to compare the working performance of our AI model with radiologists and the other models. First, a curated mini-dataset of totally 1,000 scans of brain tumor cases on MRI and cerebrovascular disease cases on brain CT will be publicly released. Teams can use this dataset to train or test on their AI models, and submit their trained algorithms or prediction results for evaluation. The performance of the uploaded models will be tested on the same testing cohort of us, and the uploaded prediction results will be compared with the generated content of us. Second, a fine-tuned offline AI-assisted systems will be embedded in the picture archiving and communication system (PACS) in the radiology department after getting permission of medical affairs department and ethics committee in some medical centers. However, radiologists in these medical centers will not get AI-generated diagnoses and reports during this stage, while the imaging reports of brain MRI and CT generated by AI and radiologists will be recorded at the same time. Third, prospective data of brain MRI and CT with corresponding imaging reports and gold standard diagnostic results will be collected from all over the world as the test data inputting to our AI model. Finally, the consistency and accuracy of the report between AI models and radiologists will be compared, with respect to the histopathology and discharge diagnosis (< 3 month) as reference.
- AI-radiologist collaboration study:
In this stage, we aim to perform generalization verification on our reasoning-enhanced neuroimaging AI in the real clinical scenarios.
Over 50 international radiologists will be recruited to perform a diagnosis study using a subset of 400 scans from the testing cohort of us. The workflow including such steps in order: imaging reading, writing initial report, making diagnosis, reading AI reasoning, revising initial report, and evaluating content generated by AI. When writing reports, radiologists will be will be randomly assigned to two groups and asked to complete half of cases with AI-assisted tools and the other half of cases without, to ensure every case will be completing by two radiologists of the same level with and without AI assistance, respectively.
The first goal of this study is to estimate the performance of the average radiologist with or without AI as well as their working efficiency and confidence at neurological diseases diagnosis on CT and MRI.
The secondary goal is to evaluate the clinical viability and superiority of reasoning-enhanced AI on human-machine collaborative task. The accuracy and completion will be compared between revised reports with initial version written by radiologists, while radiologists' inclination and diagnostic confidence will be recorded as subjective evaluation indexes.
- Conditions
- Central Nervous System Disease, MRI, CT, AI (Artificial Intelligence), Radiology
- Being tested
- AI-assisted diagnostic systems
- Medical subject headings
- Central Nervous System Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AI-assisted diagnostic systemsDiagnostic test
Diagnosing neurological diseases on CT/MRI with and without AI-assisted tools
What is being measured
The primary outcome is the main question the study is designed to answer.
AI tools vs Radiologists from Clinical silence trial
Diagnostic performance of AI models and over 50 radiologists from the Clinical silence trial study, at neurological diseases on brain CT/MRI, with respect to histopathology and discharge diagnosis as reference, to assess the working performance of neuroimaging AI diagnostic tools.
Measured: 6 months
AI-assisted diagnostic tool collaborates with Radiologists in clinical workflow
Working efficiency (time taking) and diagnostic confidence and accuracy of radiologists from AI-radiologist collaboration study, at neurological diseases on brain CT/MRI, to assess the clinical viability of AI-assisted diagnostic tool.
Measured: 6 months
Secondary outcomes (2)
Present AI vs the other AI tools uploaded from Clinical silence trial
Diagnostic performance of our AI models and the others uploaded from Clinical silence trial, at neurological diseases on brain CT/MRI, with respect to histopathology and discharge diagnosis as reference, to deduce the optimal AI models in diagnosis and report generation of neurological diseases.
Measured: 6 months
Reasoning-enhanced AI model collaborates with Radiologists in clinical workflow
Diagnostic confidence and accuracy of radiologists from AI-radiologist collaboration study, at neurological diseases on brain CT/MRI, and their trust in AI, to assess the value and clinical viability of AI model with visualized reasoning process.
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Sep 2025
- Study start1 May 2025
- Primary completion1 Oct 2030 (estimated)
- Study completion1 Dec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Central Nervous System DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 30,000 participants (estimated)
- Target duration
- 5 Years
Sponsor and investigators
- Lead sponsor
- Yaou Liu
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Yaou Liu, Beijing Tiantan Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07167043
- Sponsor's protocol ID
- 2025-A09
- Status last verified
- Sep 2025
- First submitted
- 3 Sep 2025
- Last updated
- 11 Sep 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Reasoning Artificial Intelligence Collaborate With Radiologists in Neurological Disease Interpretation and Diagnosis on CT and MRI
- ClinicalTrials.gov ID
- NCT07167043
- Acronym / sponsor ID
- 2025-A09
- Conditions
- Central Nervous System Disease, MRI, CT, AI (Artificial Intelligence), Radiology
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 30,000 participants (estimated)
- Lead sponsor
- Yaou LiuUniversity, hospital or other
- Study start
- 1 May 2025 (actual)
- Primary completion
- 1 Oct 2030 (estimated)
- Study completion
- 1 Dec 2030 (estimated)
- First posted
- 11 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This clinic trial aims to validate the working performance of radiologists with or without artificial intelligence (AI) diagnostic tool at neurological diseases diagnosis on brain CT/MRI. Routine diagnosis workflow in real clinical scenario including imaging reading, feature interpretation, differential diagnosis, writing initial report and optimizing revised version. And the gold standards of diagnosis are the histopathology references for brain tumors and the discharge diagnosis integrating all the examination results for the other neurological diseases. The performance of AI-assisted tools on diagnosing should be examined in a clinical process with multiple aspects identical to human radiologists' work before being transformed and putted to use. This study hypothesizes that AI models, trained with over 100,000 patient scans, are non-inferior to radiologists in neurological disease diagnosis on brain CT and MRI. For the secondary end-points, we investigate the performance of AI-radiologist collaboration of reasoning-enhanced AI-assisted systems. We hypothesize that, by visualizing the process of imaging interpretation and diagnosis, reasoning-enhanced AI can not only improve working performance of radiologists but also boost their trust in AI tools.
Detailed description
Neurological diseases affect over 50% of the world population, which contribute to an increasingly needs of imaging examination for screening and diagnosis. The shortage of neuroradiologists led to the excessive workload, linked with increasing of error rates and decreasing of report quality. Inexperienced radiologists struggle to make accurate diagnoses for some neurological diseases, especially brain tumors, which may lead to additional delays and a potentially meaningless examination for patients.
Artificial intelligence (AI) has shown potential to be "a tireless resident", which can rival human performance in medical imaging interpretation and assist radiologists in multiple links of clinical diagnostic work. However, clinicians recognize that "Black-box" models lacking clinical utility and interpretability face significant barriers to real-world deployment. While the reasoning-enhanced AI model, trained by a hundred thousand data, can not only achieve accurate and efficient diagnosis but also but also address the lack of explainability, transparency, and trust.
Owing to the heterogeneity of multi-modal real clinical data and complexity of neurological diseases, whether the developed AI-assisted system can truly serve as an "AI resident" facing challenges and doubts. Clinical trial is the best approach to verify the performance of diagnosis and human-machine collaboration of AI model with a wide range of users and prospective data before being approved for clinical use. Key aspects of the study design have been established in conjunction with a multi-disciplinary scientific advisory board, consisting with experts in AI, radiology, neurology, and pathology, to ensure meaningful validation of reasoning-enhanced AI model towards clinical translation.
This clinic trial contains two sub-studies:
- Clinical silence trial study for AI tools only: There are three approaches may be used in this stage to compare the working performance of our AI model with radiologists and the other models. First, a curated mini-dataset of totally 1,000 scans of brain tumor cases on MRI and cerebrovascular disease cases on brain CT will be publicly released. Teams can use this dataset to train or test on their AI models, and submit their trained algorithms or prediction results for evaluation. The performance of the uploaded models will be tested on the same testing cohort of us, and the uploaded prediction results will be compared with the generated content of us. Second, a fine-tuned offline AI-assisted systems will be embedded in the picture archiving and communication system (PACS) in the radiology department after getting permission of medical affairs department and ethics committee in some medical centers. However, radiologists in these medical centers will not get AI-generated diagnoses and reports during this stage, while the imaging reports of brain MRI and CT generated by AI and radiologists will be recorded at the same time. Third, prospective data of brain MRI and CT with corresponding imaging reports and gold standard diagnostic results will be collected from all over the world as the test data inputting to our AI model. Finally, the consistency and accuracy of the report between AI models and radiologists will be compared, with respect to the histopathology and discharge diagnosis (< 3 month) as reference.
- AI-radiologist collaboration study:
In this stage, we aim to perform generalization verification on our reasoning-enhanced neuroimaging AI in the real clinical scenarios.
Over 50 international radiologists will be recruited to perform a diagnosis study using a subset of 400 scans from the testing cohort of us. The workflow including such steps in order: imaging reading, writing initial report, making diagnosis, reading AI reasoning, revising initial report, and evaluating content generated by AI. When writing reports, radiologists will be will be randomly assigned to two groups and asked to complete half of cases with AI-assisted tools and the other half of cases without, to ensure every case will be completing by two radiologists of the same level with and without AI assistance, respectively.
The first goal of this study is to estimate the performance of the average radiologist with or without AI as well as their working efficiency and confidence at neurological diseases diagnosis on CT and MRI.
The secondary goal is to evaluate the clinical viability and superiority of reasoning-enhanced AI on human-machine collaborative task. The accuracy and completion will be compared between revised reports with initial version written by radiologists, while radiologists' inclination and diagnostic confidence will be recorded as subjective evaluation indexes.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Target follow-up
- 5 Years
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- All patient exams are of men suspected of harboring brain tumors or the other neurological diseases, with or without neurological symptoms, and without a history of prior brain surgery. Patients underwent brain CT and MRI, and were primarily examined at Beijing Tiantan hospital, between 2012-2026.
Key inclusion criteria (2 listed)
- For MRI: patients suspected of harboring brain tumors or detected with brain occupancy at initiating or other institution, who subsequently underwent brain MRI.
- For CT: patients with or without neurological symptoms, suspected of harboring ischemic, hemorrhagic, space-occupiing, degenerative brain disease, or traumatic brain injury, who subsequently underwent brain CT.
Key exclusion criteria (3 listed)
- Patients who opted-out or did not give permission to reuse clinical data.
- Patients with a history of prior brain surgery.
- Patients whose brain CT or MRI exhibit severe artifacts (e.g. heavy warping due to air, metal artifacts, heavy motion artifacts), thereby impeding the usage of the data.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AI-assisted diagnostic systemsDiagnosing neurological diseases on CT/MRI with and without AI-assisted tools | Diagnostic test | – |
Primary outcome
AI tools vs Radiologists from Clinical silence trial
Time frame: 6 months
Diagnostic performance of AI models and over 50 radiologists from the Clinical silence trial study, at neurological diseases on brain CT/MRI, with respect to histopathology and discharge diagnosis as reference, to assess the working performance of neuroimaging AI diagnostic tools.
AI-assisted diagnostic tool collaborates with Radiologists in clinical workflow
Time frame: 6 months
Working efficiency (time taking) and diagnostic confidence and accuracy of radiologists from AI-radiologist collaboration study, at neurological diseases on brain CT/MRI, to assess the clinical viability of AI-assisted diagnostic tool.
2 secondary outcomes
Present AI vs the other AI tools uploaded from Clinical silence trial
Time frame: 6 months
Reasoning-enhanced AI model collaborates with Radiologists in clinical workflow
Time frame: 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Sep 2025.
Related trials for Central Nervous System Disease
Not yet recruiting
Miniature In-line Respirator
Brain Death, Respiration, Artificial
Recruiting
Dietary Intervention for Migraine Relief
Migraine
Not yet recruitingObservational study
Registry of Central Sleep Apnea Patients Undergoing remedē System Implant
Central Sleep Apnea (Diagnosis), Central Sleep Apnea Syndrome
Recruiting
Automated Language Analysis in Neurodegenerative Diseases: Application of Artificial Intelligence Models
Alzheimer's Disease (AD), Frontotemporal Dementia (FTD)
Enrolling by invitationPhase 2
Tau PET Outcomes With Anti-amyloid Immunotherapies
Cognitive Impairment, Mild, Dementia, Mild
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Central Nervous System Disease and MRI, run by Yaou Liu at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 11 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
AI tools vs Radiologists from Clinical silence trial (time frame: 6 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2025.